Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based ...
Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 ...
The study found that some people taking SGLT2 inhibitors developed a dangerous infection called Fournier gangrene. This ...
Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...
FDA grants accelerated approval to Novartis' Vanrafia for IgA nephropathy, with Phase 3 data in 2026 expected to support ...
In patients with heart failure, SGLT2 inhibitors after TAVI are associated with major risk reductions in a clinical trial ...
Pharmaceutical Technology on MSN1d
FDA grants accelerated approval to Novartis’ Vanrafia for IgANThe approval is supported by a prespecified interim analysis from the ongoing, randomised Phase III ALIGN trial.
Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
The following is a summary of “YouTube as a source of information for stroke rehabilitation: a cross-sectional analysis of ...
The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...
Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...
Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback